Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
NCT01205438 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- March 31, 2015
- Enrollment
- 1,124 (actual)
- Sites
- 185
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune disease, connective tissue disease, systemic lupus erythematosus